GENITOURINARY TRACT INFECTIONS AND SGLT2 INHIBITORS IN HEART FAILURE: AN EMPEROR-POOLED ANALYSIS

University of Porto, Centre d'Investigations Cliniques, Baylor Scott and White Research Institute, National and Kapodistrian University of Athens, German Heart Center Charité, Baylor University Medical Center, Imperial College

Sodium glucose co-transporter-2 inhibitors (SGLT2i) have been shown to improve outcomes in heart failure patients, but their association with urinary tract infections (UTIs) raises concerns. This analysis examines the incidence of UTIs and mycotic genitourinary infections (MGIs) in heart failure patients treated with SGLT2i. The findings suggest that while SGLT2i may be linked to an increased occurrence of UTIs, the overall risk of hospitalization and mortality remains complex and warrants further investigation.